Clinical studies
SpectraCure will sponsor a North American multicenter phase l/ll – study for recurrent prostate cancer will start
in Q1 2012.
SpectraCure is also involved as co-sponsor in a phase I study on pacreatic cancer in London.
Please contact us for further information.
in Q1 2012.
SpectraCure is also involved as co-sponsor in a phase I study on pacreatic cancer in London.
Please contact us for further information.
Advancing cancer treatment with IDOSE®
